TIAN RUIXIANG HOLDINGS LTD-A (TIRX)

KYG8884K1287 - Common Stock

1.69  -0.07 (-3.98%)

After market: 1.62 -0.07 (-4.14%)

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to TIRX. TIRX was compared to 141 industry peers in the Insurance industry. While TIRX has a great health rating, there are worries on its profitability. TIRX is valued expensive and it does not seem to be growing.



1

1. Profitability

1.1 Basic Checks

TIRX had negative earnings in the past year.
TIRX had a positive operating cash flow in the past year.
In multiple years TIRX reported negative net income over the last 5 years.
The reported operating cash flow has been mixed in the past 5 years: TIRX reported negative operating cash flow in multiple years.

1.2 Ratios

The Return On Assets of TIRX (-6.46%) is worse than 94.29% of its industry peers.
The Return On Equity of TIRX (-7.59%) is worse than 83.57% of its industry peers.
Industry RankSector Rank
ROA -6.46%
ROE -7.59%
ROIC N/A
ROA(3y)-8.37%
ROA(5y)-3.34%
ROE(3y)-8.85%
ROE(5y)-3.38%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for TIRX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A

7

2. Health

2.1 Basic Checks

TIRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
TIRX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for TIRX has been increased compared to 5 years ago.
TIRX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

TIRX has an Altman-Z score of 0.52. This is a bad value and indicates that TIRX is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of TIRX (0.52) is better than 73.57% of its industry peers.
TIRX has a debt to FCF ratio of 2.67. This is a good value and a sign of high solvency as TIRX would need 2.67 years to pay back of all of its debts.
The Debt to FCF ratio of TIRX (2.67) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.04 indicates that TIRX is not too dependend on debt financing.
The Debt to Equity ratio of TIRX (0.04) is better than 87.14% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 2.67
Altman-Z 0.52
ROIC/WACCN/A
WACC7.54%

2.3 Liquidity

A Current Ratio of 5.06 indicates that TIRX has no problem at all paying its short term obligations.
TIRX's Current ratio of 5.06 is amongst the best of the industry. TIRX outperforms 95.00% of its industry peers.
A Quick Ratio of 5.06 indicates that TIRX has no problem at all paying its short term obligations.
TIRX has a Quick ratio of 5.06. This is amongst the best in the industry. TIRX outperforms 95.00% of its industry peers.
Industry RankSector Rank
Current Ratio 5.06
Quick Ratio 5.06

0

3. Growth

3.1 Past

TIRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.09%, which is quite impressive.
The Revenue has decreased by -7.96% in the past year.
Measured over the past years, TIRX shows a very negative growth in Revenue. The Revenue has been decreasing by -16.62% on average per year.
EPS 1Y (TTM)57.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.43%
Revenue 1Y (TTM)-7.96%
Revenue growth 3Y-27.38%
Revenue growth 5Y-16.62%
Sales Q2Q%-75.4%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

1

4. Valuation

4.1 Price/Earnings Ratio

TIRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of TIRX is on the same level as its industry peers.
Industry RankSector Rank
P/FCF 8.19
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

TIRX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

TIAN RUIXIANG HOLDINGS LTD-A

NASDAQ:TIRX (12/27/2024, 7:51:01 PM)

After market: 1.62 -0.07 (-4.14%)

1.69

-0.07 (-3.98%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupInsurance
GICS IndustryInsurance
Earnings (Last)10-27 2022-10-27/amc
Earnings (Next)N/A N/A
Inst Owners0.11%
Inst Owner ChangeN/A
Ins Owners11.14%
Ins Owner ChangeN/A
Market Cap4.02M
Analysts0
Price TargetN/A
Short Float %2.27%
Short Ratio0.62
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.23
P/FCF 8.19
P/OCF 8.19
P/B 0.12
P/tB 0.13
EV/EBITDA N/A
EPS(TTM)-3.87
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.21
FCFY12.21%
OCF(TTM)0.21
OCFY12.21%
SpS0.52
BVpS13.59
TBVpS12.85
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -6.46%
ROE -7.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 39.46%
ROA(3y)-8.37%
ROA(5y)-3.34%
ROE(3y)-8.85%
ROE(5y)-3.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF 2.67
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.06
Quick Ratio 5.06
Altman-Z 0.52
F-Score5
WACC7.54%
ROIC/WACCN/A
Cap/Depr(3y)7.61%
Cap/Depr(5y)119.54%
Cap/Sales(3y)0.1%
Cap/Sales(5y)2.03%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-7.43%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-7.96%
Revenue growth 3Y-27.38%
Revenue growth 5Y-16.62%
Sales Q2Q%-75.4%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.01%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y594.18%
FCF growth 3YN/A
FCF growth 5Y-6.14%
OCF growth 1Y600.15%
OCF growth 3YN/A
OCF growth 5Y-6.27%